Scientists from Kobe University (Japan) confirmed the effectiveness of Janus kinase inhibitors in the treatment of arthritis. The research was published in the journal Rheumatology.
Oral Janus kinase inhibitors have long been used to treat patients with arthritis, despite concerns about their effectiveness. In the new retrospective study, researchers used data from 622 patients treated at seven major university hospitals in Japan. They compared the effectiveness and safety of four common Janus kinase inhibitors: tofacitinib, baricitinib, peficitinib, and upadacitinib.
Approximately one in three patients achieved remission, and 75% experienced significant improvement in arthritis symptoms; This means that the drugs are quite effective. More than 80% of patients were taking study medications six months after baseline; this may be indicative of good tolerability.
The study showed the effectiveness of Janus kinase inhibitors was particularly helpful for patients with multiple diseases who did not benefit from the traditional drug methotrexate.
Rheumatoid arthritis is a common autoimmune disease characterized by chronic inflammation and destruction of joint linings, as well as various systemic complications.
Previous scientists statedIt is stated that the first treatment for cartilage restoration will be offered to patients soon.